Tumor CD20 Loss and Poor Outcome in Relapsed/Refractory (R/R) Diffuse Large B- Cell Lymphoma (DLBCL)

被引：0
|
作者：
Alchidiac, Jessy [1 ,2 ]
Hueso, Thomas [1 ]
Massard, Christophe [1 ]
Ribrag, Vincent [1 ]
Michot, Jean-Marie [1 ]
机构：
[1] Inst Gustave Roussy, Paris, France
[2] Lebanese Univ, Beirut, Lebanon
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
ABCL; relapsed/refractory non-Hodgkin Lymphoma; CD20; loss; CD20 weak expression; biopsy at relapse;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ABCL-119
引用
收藏
页码：S457 / S457
页数：1
相关论文
共 50 条
  • [31] Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy
    Di Rocco, Alice
    Di Rocco, Arianna
    Farcomeni, Alessio
    Petrucci, Luigi
    De Luca, Giulia
    Mazzon, Federico
    Martelli, Maurizio
    Foa, Robin
    BLOOD, 2019, 134
  • [32] MYC plus relapsed and refractory (R/R) diffuse large b-cell lymphoma (DLBCL): Impact of additional hits and outcomes with subsequent therapy.
    Epperla, Narendranath
    Maddocks, Kami J.
    Salhab, Mohamed
    Chavez, Julio C.
    Reddy, Nishitha M.
    Karmali, Reem
    Umyarova, Elvira
    Bachanova, Veronika
    Glenn, Martha Jane
    Xavier, Ana Carolina
    Zhou, Zheng
    Hernandez-Ilizaliturri, Francisco J.
    Barta, Stefan K.
    Lansigan, Frederick
    Mehta, Amitkumar N.
    Flowers, Christopher
    Cohen, Jonathon Brett
    Fenske, Timothy S.
    Hamadani, Mehdi
    Costa, Luciano J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] EVALUATION OF IMPACT OF PRIOR CAR T THERAPY ON PHARM ACOKIN ETICS (PK) AND PHARMACODYNAMICS (PD) OF ODRONEXTAMAB, A CD20 x CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/ REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Zhu, M.
    Meng, X.
    Brouwer-Visser, J.
    Yan, H.
    Conrado, D.
    Padros, M. Bravo
    Harnisch, L.
    Chaudhry, A.
    Mohamed, H.
    Ambati, S.
    Davis, J.
    Xu, X.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S65 - S65
  • [34] Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial
    de Vos, Sven
    Reagan, Patrick M.
    Patel, Manish R.
    Saba, Nakhle S.
    Mortlock, Andrew
    Cerec, Virginie
    Munugalavadla, Veerendra
    Acar, Melih
    Nuttall, Barrett
    Jenkins, David
    White, Rafael
    Callahan, Megan
    Forcina, Alessandra
    Roschewski, Mark
    Flinn, Ian W.
    BLOOD, 2022, 140 : 6635 - 6637
  • [35] Real-World Effectiveness of Tafasitamab (Tafa) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States
    Saverno, Kimberly
    Nastoupil, Loretta
    Feinberg, Bruce
    Galvin, John
    Pathak, Prathamesh
    Amoloja, Theresa
    Gentile, Danielle
    Asgarisabet, Parisa
    Epperla, Narendranath
    BLOOD, 2024, 144 : 2375 - 2376
  • [36] Radiotherapy Combined Chimeric Antigen Receptor T-Cells Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma(R/R DLBCL)
    Zhou, Lili
    Liu, Yifan
    Ye, Shiguang
    Li, Ping
    Li, Shaoguang
    Liang, Aibin
    BLOOD, 2023, 142
  • [37] Epcoritamab versus standard of care in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) - a phase 3 study (EPCORE DLBCL-1)
    Hess, G.
    Thieblemont, C.
    Clausen, M. R.
    Lugtenburg, P.
    Balari, Sureda A.
    Zinzani, P. L.
    Wu, J.
    Finn, L.
    Vindelov, S. D.
    Fox, C. P.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 192 - 193
  • [38] Population Pharmacokinetics and CD20 Binding Dynamics for Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL)
    Bender, Brendan C.
    Li, Chi-Chung
    Marchand, Mathilde
    Turner, David C.
    Li, Feifei
    Vadhavkar, Shweta
    Wang, Bei
    Deng, Rong
    Lu, James
    Jin, Jin
    Li, Chunze
    Yin, Shen
    Wei, Michael C.
    Chanu, Pascal
    BLOOD, 2023, 142
  • [39] Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.
    Mueller, Karen Thudium
    Grupp, Stephan A.
    Maude, Shannon L.
    Levine, John E.
    Pulsipher, Michael
    Boyer, Michael W.
    August, Keith Jason
    Myers, Gary Douglas
    Awasthi, Rakesh
    Waldron, Edward K.
    Bubuteishvili-Pacaud, Lida
    Taran, Tanya
    Cota, Mariana
    Tam, Constantine Si Lun
    Jager, Ulrich
    Foley, Ronan
    Borchmann, Peter
    Schuster, Stephen J.
    Waller, Edmund K.
    Laetsch, Theodore Willis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Gu, Juan J.
    Vacaro, Michael
    Attwood, Kris
    Mavis, Cory
    Torka, Pallawi
    Barth, Matthew J.
    Hernandez-Ilizaliturri, Francisco J.
    BLOOD, 2019, 134
12345